Skip to main content

MDRPEDIA RECORDELITE · TIER IILIVING

Moncef Slaoui

Immunology (Vaccine Development) · Operation Warp Speed (US Government) · Philadelphia, Morocco

Suggest a correction
ELITE · TIER II · MDRPEDIA · LISTED ·MTIER II
h-index (OpenAlex)
50
Papers on record
10
Citations to these papers
3,143
Stature
Tier II
EVIDENCE RECORD

What this record is built on

Compared with the register: Internal Medicine · Morocco · How it works

I · SCHOLARSHIP

h-index
50 · 70th pct
OpenAlex✓ Verified
Papers on record
10
Crossref / DOI◐ Public record
Citations received
3,143
OpenAlex◐ Public record

II · PRACTICE

Licence
Not yet checked
Medical council○ Not reported
Board certification
—
Specialty boards○ Not reported
Registration ID
—
National registry○ Not reported
Institutions
2
Institution records◐ Public record

III · LEARNING & TEACHING

Trainees traced
Not yet traced
Lineage○ Not reported
Mentors traced
Not yet traced
Lineage○ Not reported
Invited talks
—
Congress programmes○ Not reported

IV · PEER STANDING

Honours
1
Awarding bodies◐ Public record
Techniques pioneered
—
Published literature○ Not reported
Ethics mark
Not yet audited
MDRPedia audit○ Not reported

Not on this record by design:Star ratingsAnonymous reviewsPaid placement

Record

Moncef Slaoui is a Moroccan-Belgian-American immunologist who served as chief scientific advisor for Operation Warp Speed, the US government program that developed COVID-19 vaccines in record time. Previously he led vaccine development at GlaxoSmithKline for 30 years, overseeing 14 new vaccines including those for cervical cancer and malaria.
IN PLAIN WORDS
  • Research is cited 3K+ times by other doctors and scientists
  • Currently at Operation Warp Speed (US Government) in Philadelphia, Morocco

Institutions

  • Operation Warp Speed (US Government)Former Chief Scientific Advisor
  • GlaxoSmithKlineFormer Chairman of Vaccines
QUESTIONS YOU MIGHT ASK AT A FIRST VISIT
  • Is a procedure needed now, or can medicines and lifestyle changes help first?
  • What are the risks and benefits of each option for someone like me?
  • How many similar cases does your team see, and who will be involved in my care?
  • Who do I contact if symptoms come back after treatment?

Landmark papers

Papers on record
10
Citations received
3,143
Papers on record by year, 1986–2020

PUBLISHED IN New England Journal of Medicine · The Journal of Infectious Diseases · Proceedings of the National Academy of Sciences · Vaccine · Infection and Immunity

  1. 1997A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine against<i>Plasmodium falciparum</i><i>Malaria</i>New England Journal of Medicinedoi 10.1056/nejm199701093360202879 citations
  2. 2002Glycoprotein-D–Adjuvant Vaccine to Prevent Genital HerpesNew England Journal of Medicinedoi 10.1056/nejmoa011915789 citations
  3. 1995Safety, Immunogenicity, and Efficacy of a Recombinantly Produced Plasmodium falciparum Circumsporozoite Protein-Hepatitis B Surface Antigen Subunit VaccineThe Journal of Infectious Diseasesdoi 10.1093/infdis/171.6.1576329 citations
  4. 1998Long‐Term Efficacy and Immune Responses following Immunization with the RTS,S Malaria VaccineThe Journal of Infectious Diseasesdoi 10.1086/515657236 citations
  5. 2020Developing Safe and Effective Covid Vaccines — Operation Warp Speed’s Strategy and ApproachNew England Journal of Medicinedoi 10.1056/nejmp2027405225 citations
Show all 10 papersShow fewer papers
  1. 1986Nucleic acid sequence of an internal image-bearing monoclonal anti-idiotype and its comparison to the sequence of the external antigen.Proceedings of the National Academy of Sciencesdoi 10.1073/pnas.83.17.6578161 citations
  2. 1998Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant systemVaccinedoi 10.1016/s0264-410x(97)00254-5157 citations
  3. 1999Potent Induction of Focused Th1‐Type Cellular and Humoral Immune Responses by RTS,S/SBAS2, a Recombinant<i>Plasmodium falciparum</i>Malaria VaccineThe Journal of Infectious Diseasesdoi 10.1086/315074156 citations
  4. 2003Herpes Simplex Virus (HSV) Type 2 Glycoprotein D Subunit Vaccines and Protection against Genital HSV‐1 or HSV‐2 Disease in Guinea PigsThe Journal of Infectious Diseasesdoi 10.1086/374002115 citations
  5. 1996Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccineInfection and Immunitydoi 10.1128/iai.64.10.4078-4084.199696 citations

Honours

  • —Galien Foundation Prix Galien Award

Career

  • 1988Joined GlaxoSmithKlineBegan 30-year career in vaccine development at GSK
  • 2007Chairman of Global Vaccines at GSKLed development of 14 new vaccines including Cervarix (HPV) and Mosquirix (malaria)
  • 2020Chief Scientific Advisor of Operation Warp SpeedLed the US government program that developed COVID-19 vaccines in under a year

Training and certification

  • Free University of Brussels

Lineage

We haven't traced this physician's mentors and trainees yet. If you trained with them, you can add to the record.Contribute lineage
FOR THE DOCTOR

Are you Moncef Slaoui?

Claim this record to correct details, add your lineage and teaching, and embed your seal. Claims are checked against your registration before anything changes.

Share this record

Share card for Moncef Slaoui